These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

79 related items for PubMed ID: 7495981

  • 21. Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase.
    Tan M, Grijalva R, Yu D.
    Cancer Res; 1999 Apr 01; 59(7):1620-5. PubMed ID: 10197638
    [Abstract] [Full Text] [Related]

  • 22. Proliferation-differentiation relationships in the expression of heparin-binding epidermal growth factor-related factors and erbB receptors by normal and psoriatic human keratinocytes.
    Piepkorn M, Predd H, Underwood R, Cook P.
    Arch Dermatol Res; 2003 Jul 01; 295(3):93-101. PubMed ID: 12768307
    [Abstract] [Full Text] [Related]

  • 23. ErbB-3 mediates differential mitogenic effects of NDF/heregulin isoforms on mouse keratinocytes.
    Marikovsky M, Lavi S, Pinkas-Kramarski R, Karunagaran D, Liu N, Wen D, Yarden Y.
    Oncogene; 1995 Apr 06; 10(7):1403-11. PubMed ID: 7731691
    [Abstract] [Full Text] [Related]

  • 24. ErbB kinases and NDF signaling in human prostate cancer cells.
    Grasso AW, Wen D, Miller CM, Rhim JS, Pretlow TG, Kung HJ.
    Oncogene; 1997 Nov 27; 15(22):2705-16. PubMed ID: 9400997
    [Abstract] [Full Text] [Related]

  • 25. Neu and its ligands: from an oncogene to neural factors.
    Peles E, Yarden Y.
    Bioessays; 1993 Dec 27; 15(12):815-24. PubMed ID: 7908191
    [Abstract] [Full Text] [Related]

  • 26. Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor.
    Witters L, Scherle P, Friedman S, Fridman J, Caulder E, Newton R, Lipton A.
    Cancer Res; 2008 Sep 01; 68(17):7083-9. PubMed ID: 18757423
    [Abstract] [Full Text] [Related]

  • 27. Growth factor-independent proliferation of rat mammary carcinoma cells by autocrine secretion of neu-differentiation factor/heregulin and transforming growth factor-alpha.
    Ethier SP, Langton BC, Dilts CA.
    Mol Carcinog; 1996 Feb 01; 15(2):134-43. PubMed ID: 8599580
    [Abstract] [Full Text] [Related]

  • 28. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair.
    Arteaga CL, Winnier AR, Poirier MC, Lopez-Larraza DM, Shawver LK, Hurd SD, Stewart SJ.
    Cancer Res; 1994 Jul 15; 54(14):3758-65. PubMed ID: 7913407
    [Abstract] [Full Text] [Related]

  • 29. Blocking HER-2/HER-3 function with a dominant negative form of HER-3 in cells stimulated by heregulin and in breast cancer cells with HER-2 gene amplification.
    Ram TG, Schelling ME, Hosick HL.
    Cell Growth Differ; 2000 Mar 15; 11(3):173-83. PubMed ID: 10768865
    [Abstract] [Full Text] [Related]

  • 30. Differential heat stress stability of epidermal growth factor receptor and erbB-2 receptor tyrosine kinase activities.
    Liu SM, Carpenter G.
    J Cell Physiol; 1993 Nov 15; 157(2):237-42. PubMed ID: 7901224
    [Abstract] [Full Text] [Related]

  • 31. Src family kinases and HER2 interactions in human breast cancer cell growth and survival.
    Belsches-Jablonski AP, Biscardi JS, Peavy DR, Tice DA, Romney DA, Parsons SJ.
    Oncogene; 2001 Mar 22; 20(12):1465-75. PubMed ID: 11313890
    [Abstract] [Full Text] [Related]

  • 32. Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network.
    Tzahar E, Moyer JD, Waterman H, Barbacci EG, Bao J, Levkowitz G, Shelly M, Strano S, Pinkas-Kramarski R, Pierce JH, Andrews GC, Yarden Y.
    EMBO J; 1998 Oct 15; 17(20):5948-63. PubMed ID: 9774339
    [Abstract] [Full Text] [Related]

  • 33. Modulation of breast cancer progression and differentiation by the gp30/heregulin [correction of neregulin].
    Staebler A, Sommers C, Mueller SC, Byers S, Thompson EW, Lupu R.
    Breast Cancer Res Treat; 1994 Oct 15; 31(2-3):175-82. PubMed ID: 7881097
    [Abstract] [Full Text] [Related]

  • 34. The significance of heregulin in breast cancer tumor progression and drug resistance.
    Lupu R, Cardillo M, Cho C, Harris L, Hijazi M, Perez C, Rosenberg K, Yang D, Tang C.
    Breast Cancer Res Treat; 1996 Oct 15; 38(1):57-66. PubMed ID: 8825123
    [Abstract] [Full Text] [Related]

  • 35. ErbB-3 and ErbB-4 function as the respective low and high affinity receptors of all Neu differentiation factor/heregulin isoforms.
    Tzahar E, Levkowitz G, Karunagaran D, Yi L, Peles E, Lavi S, Chang D, Liu N, Yayon A, Wen D.
    J Biol Chem; 1994 Oct 07; 269(40):25226-33. PubMed ID: 7929212
    [Abstract] [Full Text] [Related]

  • 36. The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer.
    Gullick WJ, Srinivasan R.
    Breast Cancer Res Treat; 1998 Oct 07; 52(1-3):43-53. PubMed ID: 10066071
    [Abstract] [Full Text] [Related]

  • 37. neu(c-erbB-2/HER2) and the epidermal growth factor receptor (EGFR) in breast cancer.
    Jardines L, Weiss M, Fowble B, Greene M.
    Pathobiology; 1993 Oct 07; 61(5-6):268-82. PubMed ID: 7905269
    [Abstract] [Full Text] [Related]

  • 38. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer.
    Lafky JM, Wilken JA, Baron AT, Maihle NJ.
    Biochim Biophys Acta; 2008 Apr 07; 1785(2):232-65. PubMed ID: 18291115
    [Abstract] [Full Text] [Related]

  • 39. [HER-ErbB family of receptors and their ligands: mechanisms of activation, signals and deregulation in cancer].
    L'Allemain G.
    Bull Cancer; 2003 Nov 07; 90 Spec No():S179-85. PubMed ID: 14763137
    [Abstract] [Full Text] [Related]

  • 40. The deaf and the dumb: the biology of ErbB-2 and ErbB-3.
    Citri A, Skaria KB, Yarden Y.
    Exp Cell Res; 2003 Mar 10; 284(1):54-65. PubMed ID: 12648465
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.